BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23721148)

  • 1. Treatment response in the neck: p16+ versus p16- oropharyngeal cancer.
    Mak D; Hicks RJ; Rischin D; Solomon B; Peters L; Bressel M; Young RJ; Corry J
    J Med Imaging Radiat Oncol; 2013 Jun; 57(3):364-72. PubMed ID: 23721148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of PET-CT nodal SUVmax with p16 positivity in oropharyngeal squamous cell carcinoma.
    Clark J; Jeffery CC; Zhang H; Cooper T; O'Connell DA; Harris J; Seikaly H; Biron VL
    J Otolaryngol Head Neck Surg; 2015 Sep; 44(1):37. PubMed ID: 26374294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p16 status and interval neck dissection findings after a 'clinically complete response' to chemoradiotherapy in oropharyngeal squamous cell carcinoma.
    Miah MS; Spielmann P; White SJ; Kennedy C; Kernohan N; Mountain RE; Cassasola R; Mahendran S
    J Laryngol Otol; 2015 Aug; 129(8):801-6. PubMed ID: 26087671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: the role of US, MRI and FDG-PET/TC scans to assess residual neck disease.
    Pellini R; Manciocco V; Turri-Zanoni M; Vidiri A; Sanguineti G; Marucci L; Sciuto R; Covello R; Sperduti I; Kayal R; Anelli V; Pichi B; Mercante G; Spriano G
    J Craniomaxillofac Surg; 2014 Dec; 42(8):1834-9. PubMed ID: 25150165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Tumor Size and p16 Status on Treatment Outcomes - Achievement of Complete Remission in Prospectively Followed Patients with Oropharyngeal Tumors.
    Slavik M; Kazda T; Selingerová I; Šána J; Ahmad P; Gurín D; Hermanová M; Novotný T; Červená R; Dymáčková R; Burkoň P; Slabý O; Šlampa P
    Klin Onkol; 2019; 32(1):58-65. PubMed ID: 30764631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response evaluation of the neck in oropharyngeal cancer: Value of magnetic resonance imaging and influence of p16 in selecting patients for post-radiotherapy neck dissection.
    Lilja-Fischer JK; Jensen K; Eskildsen HW; Fink-Jensen V; Nielsen VE
    Acta Oncol; 2015; 54(9):1599-606. PubMed ID: 26198649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic nodal metastasis in patients with oropharyngeal squamous cell carcinoma receiving chemoradiotherapy: Relationship with human papillomavirus status and failure patterns.
    Huang YH; Yeh CH; Cheng NM; Lin CY; Wang HM; Ko SF; Toh CH; Yen TC; Liao CT; Ng SH
    PLoS One; 2017; 12(7):e0180779. PubMed ID: 28686646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term regional control in the observed neck following definitive chemoradiation for node-positive oropharyngeal squamous cell cancer.
    Goenka A; Morris LG; Rao SS; Wolden SL; Wong RJ; Kraus DH; Ohri N; Setton J; Lok BH; Riaz N; Mychalczak BR; Schoder H; Ganly I; Shah JP; Pfister DG; Zelefsky MJ; Lee NY
    Int J Cancer; 2013 Sep; 133(5):1214-21. PubMed ID: 23436584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
    Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
    J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer.
    Trinkaus ME; Hicks RJ; Young RJ; Peters LJ; Solomon B; Bressel M; Corry J; Fisher R; Binns D; McArthur GA; Rischin D
    J Med Imaging Radiat Oncol; 2014 Feb; 58(1):89-97. PubMed ID: 24529061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129.
    Galloway TJ; Zhang QE; Nguyen-Tan PF; Rosenthal DI; Soulieres D; Fortin A; Silverman CL; Daly ME; Ridge JA; Hammond JA; Le QT
    Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):362-371. PubMed ID: 27478170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitfalls of post-treatment PET after de-intensified chemoradiotherapy for HPV-associated oropharynx cancer: Secondary analysis of a phase 2 trial.
    Wang K; Wong TZ; Amdur RJ; Mendenhall WM; Sheets NC; Green R; Thorp BD; Patel SN; Hackman TG; Zanation AM; Weissler MC; Chera BS
    Oral Oncol; 2018 Mar; 78():108-113. PubMed ID: 29496037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma.
    Oguejiofor KK; Hall JS; Mani N; Douglas C; Slevin NJ; Homer J; Hall G; West CM
    Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):630-8. PubMed ID: 23916365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters.
    Fischer CA; Kampmann M; Zlobec I; Green E; Tornillo L; Lugli A; Wolfensberger M; Terracciano LM
    Ann Oncol; 2010 Oct; 21(10):1961-1966. PubMed ID: 20423915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease.
    Bhattasali O; Han J; Thompson LDR; Buchschacher GL; Abdalla IA; Iganej S
    Oral Oncol; 2018 Mar; 78():151-155. PubMed ID: 29496043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation.
    Broglie MA; Soltermann A; Rohrbach D; Haile SR; Pawlita M; Studer G; Huber GF; Moch H; Stoeckli SJ
    Head Neck; 2013 Dec; 35(12):1698-706. PubMed ID: 23508511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status.
    Kikuchi M; Koyasu S; Shinohara S; Usami Y; Imai Y; Hino M; Itoh K; Tona R; Kanazawa Y; Kishimoto I; Harada H; Naito Y
    Head Neck; 2015 Oct; 37(10):1524-31. PubMed ID: 24890445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma.
    Skillington SA; Kallogjeri D; Lewis JS; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2017 Mar; 143(3):253-259. PubMed ID: 27918781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic contrast-enhanced MRI, diffusion-weighted MRI and
    Ng SH; Liao CT; Lin CY; Chan SC; Lin YC; Yen TC; Chang JT; Ko SF; Fan KH; Wang HM; Yang LY; Wang JJ
    Eur Radiol; 2016 Nov; 26(11):4162-4172. PubMed ID: 26911889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting residual neck disease in patients with oropharyngeal squamous cell carcinoma treated with radiation therapy: utility of p16 status.
    Shonka DC; Shoushtari AN; Thomas CY; Moskaluk C; Read PW; Reibel JF; Levine PA; Jameson MJ
    Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1126-32. PubMed ID: 19917926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.